ALT5 Sigma Corp
ALTS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ALTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALTS
ALT5 Sigma Corp (ALTS) is a dual-segment company operating a blockchain-powered fintech platform and a biotechnology pipeline focused on non-addictive pain treatments, with its biotech segment classified as discontinued operations and its liquidity profile recently strengthened by large WLFI token holdings.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 28, 2026.
ALT5 Sigma Corp (ALTS) is a dual-segment company operating a blockchain-powered fintech platform and a biotechnology pipeline focused on non-addictive pain treatments, with its biotech segment classified as discontinued operations and its liquidity profile recently strengthened by large WLFI token holdings.
- Cash and equivalents $10.5M as of 2026-03-28 [sec (latest financials)].
- Total revenue $4.7M; net income -$271.5M for the period ended 2026-03-28 [sec (latest financials)].
- Shareholders' equity $1,151.8M and total debt $4.9M as of 2026-03-28 [sec (latest financials)].
- Biotechnology segment is presented as discontinued operations for the 13 weeks ended March 28, 2026 [sec_mda · as of 2026-05-18].
- Management believes conditions giving rise to prior going concern disclosure have been substantially mitigated due to availability of WLFI token holdings [sec · filed 2026-06-10].
What works
- The availability for use of a substantial portion of the Company's WLFI token holdings materially strengthens the Company's liquidity profile [sec · filed 2026-06-10].
- Management believes the Company possesses sufficient liquidity and financial resources to fund operations and satisfy obligations for at least the next 12 months [sec · filed 2026-06-10].
- Shareholders' equity of $1,151.8M as of 2026-03-28 provides a large capital base [sec (latest financials)].
- The Fintech segment provides blockchain-powered technologies for digital asset management, a growing market [sec_mda · as of 2026-04-13].
What to weigh
- Net loss from continuing operations was approximately $271.3 million for the 13 weeks ended March 28, 2026 [sec_mda · as of 2026-05-18].
- Net negative working capital of approximately $6.9 million as of March 28, 2026, with current liabilities exceeding current assets [sec_mda · as of 2026-05-18].
- Cash used in operations was approximately $12.3 million for the 13 weeks ended March 28, 2026 [sec_mda · as of 2026-05-18].
- The biotechnology segment is being decoupled and presented as discontinued operations, creating uncertainty about future pipeline financing [sec_mda · as of 2026-05-18].
From the filings
Quoted directly from source documents.
Management believes going concern conditions have been substantially mitigated.
“the Company believes it possesses sufficient liquidity and financial resources to fund its anticipated operations and satisfy its obligations for at least the next 12 months. Accordingly, management's current belief is that the conditions that gave rise to the previously disclosed substantial doubt regarding the Company's ability to continue as a going concern have been substantially mitigated.”
SEC filings · June 10, 2026
Large net loss from continuing operations in Q1 2026.
“net loss from continuing operations of approximately $271.3 million for the 13 weeks ended March 28, 2026”
SEC MD&A · May 18, 2026
Biotech segment is discontinued operations.
“The Biotech segment is being presented as discontinued operations for the 13 weeks ended March 28, 2026 and March 29, 2025”
SEC MD&A · May 18, 2026
Negative working capital position as of March 28, 2026.
“total current assets of approximately $32.2 million and total current liabilities of approximately $39.1 million resulting in a net negative working capital of approximately $6.9 million”
SEC MD&A · May 18, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Although management believes conditions are mitigated, the company had previously disclosed substantial doubt about its ability to continue as a going concern [sec · filed 2026-06-10].
- Negative working capital — Net negative working capital of $6.9M as of March 28, 2026, indicating potential short-term liquidity pressure [sec_mda · as of 2026-05-18].
- Dependence on WLFI token value — Liquidity improvement relies on the market value of WLFI token holdings, which is volatile [sec · filed 2026-06-10].
- Financing for biotech pipeline — The company needs additional capital to fund Phase 2b trials and biotech subsidiary, with no assurance of obtaining financing [sec_mda · as of 2026-05-18].
What to watch
- Progress of Phase 2b clinical trials for the biotech segment, as funding is required [sec_mda · as of 2026-05-18].
- Any updates on the planned decoupling and financing of the biotechnology subsidiary [sec_mda · as of 2026-05-18].
- Changes in the market value of the company's WLFI token holdings, which impacts liquidity [sec · filed 2026-06-10].
- Ability to raise additional debt or equity financing to support operations and pipeline [sec_mda · as of 2026-05-18].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated July 19, 2026 · How we verify sources →
Run ALT5 Sigma Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ALT5 Sigma Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
4.9 months
D/E 0.07 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
91
Total value held
$62.7M
| Holder | Shares | Value |
|---|---|---|
| crcm lp | 12,611,530 | $14.0M |
| vanguard capital management llc | 10,959,302 | $12.2M |
| diametric capital, lp | 6,200,620 | $6.9M |
| prelude capital management, llc | 2,950,155 | $3.3M |
| blackrock, inc. | 2,792,324 | $3.1M |
| exoduspoint capital management, lp | 2,254,910 | $2.5M |
| hunting hill global capital, llc | 1,924,603 | $2.1M |
| ubs group ag | 1,891,618 | $2.1M |
| citadel advisors llc | 1,650,249 | $1.8M |
| millennium management llc | 1,508,918 | $1.7M |
Showing top 10 of 91 institutional holders of ALT5 Sigma Corp. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 11.9%
- Days to cover
- 5.7
- Shares short
- 15,096,750
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALTS short interestGovernance
Frequently asked questions
What is the AI investment thesis for ALT5 Sigma Corp?
ALT5 Sigma Corp (ALTS) is a dual-segment company operating a blockchain-powered fintech platform and a biotechnology pipeline focused on non-addictive pain treatments, with its biotech segment classified as discontinued operations and its liquidity profile recently strengthened by large WLFI token holdings.
Who is the CEO of ALT5 Sigma Corp?
Mr. Antonios Isaac is the chief executive officer of ALT5 Sigma Corp (ALTS).
Where is ALT5 Sigma Corp headquartered?
ALT5 Sigma Corp (ALTS) is headquartered in Las Vegas, NV, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.